Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity, PBM reform, issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health, BIOSECURE Act, and the Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492).
2025 · 1st Quarter (Jan 1 - Mar 31)
OTSUKA AMERICA PHARMACEUTICAL, INC.
Filed by OTSUKA AMERICA PHARMACEUTICAL, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 17, 2025
- Income
- Not reported
- Expenses
- $1,180,000.00
- Registrant
- OTSUKA AMERICA PHARMACEUTICAL, INC.
- Filing UUID
- 4bb7871f-5120-4277-b7b6-165eea06b7d7
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Provisions related to the Continuing Appropriations and Other Matters Act, 2025; and issues related to budget reconciliation.
Issues related to tax reform efforts, issues stemming from the Tax Cuts and Jobs Act of 2017, and other corporate tax issues.
Veterans Affairs, Mental Health, and post-traumatic stress disorder (PTSD). Specifically, health care policies relating to mental health and PTSD. Veterans Affairs authorizations and appropriations issues related to mental health and PTSD.
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.